{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:43:34Z","timestamp":1783035814395,"version":"3.54.6"},"reference-count":116,"publisher":"European Respiratory Society (ERS)","issue":"160","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2021,4,2]]},"published-print":{"date-parts":[[2021,6,30]]},"abstract":"<jats:p>Patient-reported outcome measures (PROMs), tools to assess patient self-report of health status, are now increasingly used in research, care and policymaking. While there are two well-developed disease-specific PROMs for interstitial lung diseases (ILD) and idiopathic pulmonary fibrosis (IPF), many unmet and urgent needs remain. In December 2019, 64 international ILD experts convened in Erice, Italy to deliberate on many topics, including PROMs in ILD. This review summarises the history of PROMs in ILD, shortcomings of the existing tools, challenges of development, validation and implementation of their use in clinical trials, and the discussion held during the meeting. Development of disease-specific PROMs for ILD including IPF with robust methodology and validation in concordance with guidance from regulatory authorities have increased user confidence in PROMs. Minimal clinically important difference for bidirectional changes may need to be developed. Cross-cultural validation and linguistic adaptations are necessary in addition to robust psychometric properties for effective PROM use in multinational clinical trials. PROM burden of use should be reduced through appropriate use of digital technologies and computerised adaptive testing. Active patient engagement in all stages from development, testing, choosing and implementation of PROMs can help improve probability of success and further growth.<\/jats:p>","DOI":"10.1183\/16000617.0026-2021","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T07:10:24Z","timestamp":1622013024000},"page":"210026","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?"],"prefix":"10.1183","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4645-6292","authenticated-orcid":false,"given":"Meena","family":"Kalluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-5947","authenticated-orcid":false,"given":"Fabrizio","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Vancheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vancheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1373-8197","authenticated-orcid":false,"given":"Elisabetta","family":"Balestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Varone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Mogulkoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1054-5261","authenticated-orcid":false,"given":"Giulia","family":"Cacopardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Calvello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Libra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-9767","authenticated-orcid":false,"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-6963","authenticated-orcid":false,"given":"Elisabeth","family":"Bendstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"2024102403545114000_30.160.210026.1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"2024102403545114000_30.160.210026.2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-3-61"},{"key":"2024102403545114000_30.160.210026.3","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816686743"},{"key":"2024102403545114000_30.160.210026.4","unstructured":"International Alliance of Patients\u2019 Organizations (IAPO) . What is Patient-Centred Healthcare? A Review of Definitions and Principles. 2007, London, IAPO."},{"key":"2024102403545114000_30.160.210026.5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2017"},{"key":"2024102403545114000_30.160.210026.6","first-page":"A2754","article-title":"Effects of nintedanib on dyspnea, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial","volume":"201","author":"Swigris","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403545114000_30.160.210026.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0145-5"},{"key":"2024102403545114000_30.160.210026.8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12890-017-0468-5","article-title":"Unmet needs in the treatment of idiopathic pulmonary fibrosis \u2013 insights from patient chart review in five European countries","volume":"17","author":"Maher","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2024102403545114000_30.160.210026.9","doi-asserted-by":"crossref","first-page":"00124\u20132019","DOI":"10.1183\/23120541.00124-2019","article-title":"Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey","volume":"5","author":"Moor","year":"2019","journal-title":"ERJ Open Res"},{"key":"2024102403545114000_30.160.210026.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01204-2015"},{"key":"2024102403545114000_30.160.210026.11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.amjmed.2019.08.032","article-title":"What patients with idiopathic pulmonary fibrosis and caregivers want: filling the gaps with patient reported outcomes and experience measures","volume":"133","author":"Kalluri","year":"2020","journal-title":"Am J Med"},{"key":"2024102403545114000_30.160.210026.12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7812\/TPP\/09.996","article-title":"Narrative-based medicine: potential, pitfalls, and practice","volume":"13","author":"Kalitzkus","year":"2009","journal-title":"Perm J"},{"key":"2024102403545114000_30.160.210026.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2003.65309.x"},{"key":"2024102403545114000_30.160.210026.14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/bjaed\/mkw060","article-title":"Patient-reported outcome measures and patient-reported experience measures","volume":"17","author":"Kingsley","year":"2017","journal-title":"BJA Education"},{"key":"2024102403545114000_30.160.210026.15","doi-asserted-by":"crossref","first-page":"2333721417700759","DOI":"10.1177\/2333721417700759","article-title":"Patient-centered outcomes research and patient-centered care for older adults: a perspective","volume":"3","author":"Jayadevappa","year":"2017","journal-title":"Gerontol Geriatr Med"},{"key":"2024102403545114000_30.160.210026.16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/PROM.S156291","article-title":"PROMs data: can it be used to make decisions for individual patients? A narrative review","volume":"10","author":"Field","year":"2019","journal-title":"Patient Relat Outcome Meas"},{"key":"2024102403545114000_30.160.210026.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f167"},{"key":"2024102403545114000_30.160.210026.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7818"},{"key":"2024102403545114000_30.160.210026.19","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0596-1"},{"key":"2024102403545114000_30.160.210026.20","doi-asserted-by":"publisher","DOI":"10.2196\/ijmr.2885"},{"key":"2024102403545114000_30.160.210026.21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/17460441.2016.1193148","article-title":"Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data","volume":"11","author":"Basch","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"2024102403545114000_30.160.210026.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1707537"},{"key":"2024102403545114000_30.160.210026.23","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000289"},{"key":"2024102403545114000_30.160.210026.24","doi-asserted-by":"publisher","DOI":"10.4137\/hsi.s11093"},{"key":"2024102403545114000_30.160.210026.25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1378\/chest.11-2602","article-title":"Patient-reported outcomes in idiopathic pulmonary fibrosis research","volume":"142","author":"Swigris","year":"2012","journal-title":"Chest"},{"key":"2024102403545114000_30.160.210026.26","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0475-4"},{"key":"2024102403545114000_30.160.210026.27","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000091"},{"key":"2024102403545114000_30.160.210026.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0006PP"},{"key":"2024102403545114000_30.160.210026.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-571OC"},{"key":"2024102403545114000_30.160.210026.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042976"},{"key":"2024102403545114000_30.160.210026.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200709-1446OC"},{"key":"2024102403545114000_30.160.210026.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60551-1"},{"key":"2024102403545114000_30.160.210026.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002110"},{"key":"2024102403545114000_30.160.210026.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201011-1874OC"},{"key":"2024102403545114000_30.160.210026.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024102403545114000_30.160.210026.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690"},{"key":"2024102403545114000_30.160.210026.37","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"2024102403545114000_30.160.210026.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024102403545114000_30.160.210026.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2024102403545114000_30.160.210026.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102403545114000_30.160.210026.41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102403545114000_30.160.210026.42","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N Engl J Med"},{"key":"2024102403545114000_30.160.210026.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2024102403545114000_30.160.210026.44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102403545114000_30.160.210026.45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102403545114000_30.160.210026.46","first-page":"CD006322","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"2","author":"Dowman","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102403545114000_30.160.210026.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(06)80166-6"},{"key":"2024102403545114000_30.160.210026.48","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.6.1321"},{"key":"2024102403545114000_30.160.210026.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80089-2"},{"key":"2024102403545114000_30.160.210026.50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12955-014-0124-1","article-title":"The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review","volume":"12","author":"Swigris","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"2024102403545114000_30.160.210026.51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12931-019-1169-9","article-title":"Validation of the IPF-specific version of St. George's Respiratory Questionnaire","volume":"20","author":"Prior","year":"2019","journal-title":"Respir Res"},{"key":"2024102403545114000_30.160.210026.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.09.006"},{"key":"2024102403545114000_30.160.210026.53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/resp.13293","article-title":"Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease","volume":"23","author":"Suzuki","year":"2018","journal-title":"Respirology"},{"key":"2024102403545114000_30.160.210026.54","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2015"},{"key":"2024102403545114000_30.160.210026.55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12931-020-01359-3","article-title":"Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis","volume":"21","author":"Prior","year":"2020","journal-title":"Respir Res"},{"key":"2024102403545114000_30.160.210026.56","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.139121"},{"key":"2024102403545114000_30.160.210026.57","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-214944"},{"key":"2024102403545114000_30.160.210026.58","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-13"},{"key":"2024102403545114000_30.160.210026.59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12890-020-1116-z","article-title":"Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease","volume":"20","author":"Bae","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2024102403545114000_30.160.210026.60","doi-asserted-by":"publisher","DOI":"10.1136\/thx.42.10.773"},{"key":"2024102403545114000_30.160.210026.61","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201581"},{"key":"2024102403545114000_30.160.210026.62","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000363"},{"key":"2024102403545114000_30.160.210026.63","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00281-2019"},{"key":"2024102403545114000_30.160.210026.64","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2024102403545114000_30.160.210026.65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12931-019-1010-5","article-title":"Psychometric properties and minimal important differences of SF-36 in idiopathic pulmonary fibrosis","volume":"20","author":"Witt","year":"2019","journal-title":"Respir Res"},{"key":"2024102403545114000_30.160.210026.66","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1164\/rccm.202002-0415OC","article-title":"Development and initial validation analyses of the Living with Idiopathic Pulmonary Fibrosis (L-IPF) questionnaire","volume":"202","author":"Swigris","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403545114000_30.160.210026.67","first-page":"A7707","article-title":"Preliminary testing of the Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure (IPF PRoM)","volume":"197","author":"Russell","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403545114000_30.160.210026.68","first-page":"A1031","article-title":"Development and preliminary testing of the Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure (IPF-PRoM): UK and Ireland Multi-Centre Study","volume":"195","author":"Russell","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403545114000_30.160.210026.69","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.3.619"},{"key":"2024102403545114000_30.160.210026.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.06.018"},{"key":"2024102403545114000_30.160.210026.71","doi-asserted-by":"publisher","DOI":"10.1097\/00008483-200511000-00011"},{"key":"2024102403545114000_30.160.210026.72","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.118521"},{"key":"2024102403545114000_30.160.210026.73","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0693"},{"key":"2024102403545114000_30.160.210026.74","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.339"},{"key":"2024102403545114000_30.160.210026.75","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-4"},{"key":"2024102403545114000_30.160.210026.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.06.009"},{"key":"2024102403545114000_30.160.210026.77","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5539\/gjhs.v5n6p131","article-title":"Content validity of CASA-Q cough domains and UCSD-SOBQ for use in patients with idiopathic pulmonary fibrosis","volume":"5","author":"Gries","year":"2013","journal-title":"Glob J Health Sci"},{"key":"2024102403545114000_30.160.210026.78","doi-asserted-by":"crossref","first-page":"1530028","DOI":"10.1080\/20018525.2018.1530028","article-title":"Validation of the COPD Assessment Test (CAT) in patients with idiopathic pulmonary fibrosis","volume":"5","author":"Grufstedt","year":"2018","journal-title":"Eur Clin Respir J"},{"key":"2024102403545114000_30.160.210026.79","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0808-x"},{"key":"2024102403545114000_30.160.210026.80","unstructured":"U.S. Food and Drug Administration . Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. www.fda.gov\/media\/77832\/download"},{"key":"2024102403545114000_30.160.210026.81","unstructured":"European Medicines Agency . Reflection Paper on the Regulatory Guidance for the Use of Health Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. 2005. www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf"},{"key":"2024102403545114000_30.160.210026.82","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12890-019-1018-0","article-title":"Validation of the King's Brief Interstitial Lung Disease questionnaire in idiopathic pulmonary fibrosis","volume":"19","author":"Prior","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2024102403545114000_30.160.210026.83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","article-title":"Patient reported outcome measures in rare diseases: a narrative review","volume":"13","author":"Slade","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2024102403545114000_30.160.210026.84","unstructured":"Willis GB . Cognitive Interviewing: A Tool for Improving Questionnaire Design. 1st Edn. Thousand Oaks: Sage Publications, 2004."},{"key":"2024102403545114000_30.160.210026.85","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MCP.0000000000000294","article-title":"New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?","volume":"22","author":"Wijsenbeek","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"2024102403545114000_30.160.210026.86","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00152609"},{"key":"2024102403545114000_30.160.210026.87","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050666"},{"key":"2024102403545114000_30.160.210026.88","doi-asserted-by":"publisher","DOI":"10.1249\/00005768-198205000-00012"},{"key":"2024102403545114000_30.160.210026.89","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fmed.2017.00226","article-title":"Integrating patient perspectives into personalized medicine in idiopathic pulmonary fibrosis","volume":"4","author":"Moor","year":"2017","journal-title":"Front Med"},{"key":"2024102403545114000_30.160.210026.90","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2870"},{"key":"2024102403545114000_30.160.210026.91","doi-asserted-by":"publisher","DOI":"10.1186\/1745-9974-6-4"},{"key":"2024102403545114000_30.160.210026.92","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(02)00392-6"},{"key":"2024102403545114000_30.160.210026.93","doi-asserted-by":"crossref","first-page":"1853658","DOI":"10.1080\/20018525.2020.1853658","article-title":"Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment","volume":"8","author":"K\u00f8lner-Augustson","year":"2020","journal-title":"Eur Clin Respir J"},{"key":"2024102403545114000_30.160.210026.94","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0621-y"},{"key":"2024102403545114000_30.160.210026.95","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12955-020-01462-5","article-title":"The development and cognitive testing of the positive outcomes HIV PROM: a brief novel patient-reported outcome measure for adults living with HIV","volume":"18","author":"Bristowe","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2024102403545114000_30.160.210026.96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-020-1298-1","article-title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS\u00ae trials","volume":"21","author":"Kreuter","year":"2020","journal-title":"Respir Res"},{"key":"2024102403545114000_30.160.210026.97","doi-asserted-by":"crossref","first-page":"zsy013","DOI":"10.1093\/sleep\/zsy013","article-title":"Development and early validation of a patient-reported outcome measure to assess sleep amongst people experiencing problems with alcohol or other drugs","volume":"41","author":"Neale","year":"2018","journal-title":"Sleep"},{"key":"2024102403545114000_30.160.210026.98","doi-asserted-by":"publisher","DOI":"10.1007\/BF02310555"},{"key":"2024102403545114000_30.160.210026.99","doi-asserted-by":"publisher","DOI":"10.1007\/BF02289289"},{"key":"2024102403545114000_30.160.210026.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.09.032"},{"key":"2024102403545114000_30.160.210026.101","first-page":"29","article-title":"Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis","volume":"7","author":"Olson","year":"2016","journal-title":"Patient Relat Outcome Meas"},{"key":"2024102403545114000_30.160.210026.102","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00036813"},{"key":"2024102403545114000_30.160.210026.103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/COPD.S219480","article-title":"Minimal clinically important differences for patient-reported outcome measures of cough and sputum in patients with COPD","volume":"15","author":"Rebelo","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102403545114000_30.160.210026.104","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12890-018-0738-x","article-title":"Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life","volume":"18","author":"Rajala","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2024102403545114000_30.160.210026.105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12955-020-01344-w","article-title":"How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods","volume":"18","author":"Mouelhi","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2024102403545114000_30.160.210026.106","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jval.2018.07.875","article-title":"Perceptions of response burden associated with completion of patient-reported outcome assessments in oncology","volume":"22","author":"Atkinson","year":"2019","journal-title":"Value Health"},{"key":"2024102403545114000_30.160.210026.107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41533-017-0023-0","article-title":"Feasibility and applicability of the paper and electronic COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ) in primary care: a clinimetric study.","volume":"27","author":"Kocks","year":"2017","journal-title":"NPJ Prim Care Respir Med"},{"key":"2024102403545114000_30.160.210026.108","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20120173"},{"key":"2024102403545114000_30.160.210026.109","doi-asserted-by":"publisher","DOI":"10.1177\/014662168200600408"},{"key":"2024102403545114000_30.160.210026.110","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.2196\/jmir.1785","article-title":"A web-based computerized adaptive testing (CAT) to assess patient perception in hospitalization","volume":"13","author":"Chien","year":"2011","journal-title":"J Med Internet Res"},{"key":"2024102403545114000_30.160.210026.111","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00014"},{"key":"2024102403545114000_30.160.210026.112","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"2024102403545114000_30.160.210026.113","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017282"},{"key":"2024102403545114000_30.160.210026.114","doi-asserted-by":"publisher","DOI":"10.2165\/11597150-000000000-00000"},{"key":"2024102403545114000_30.160.210026.115","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000129"},{"key":"2024102403545114000_30.160.210026.116","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-017-1577-6","article-title":"Beyond study participants: a framework for engaging patients in the selection or development of clinical outcome assessments for evaluating the benefits of treatment in medical product development","volume":"27","author":"Wilson","year":"2018","journal-title":"Qual Life Res"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0026-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:03:04Z","timestamp":1740373384000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0026-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":116,"journal-issue":{"issue":"160","published-online":{"date-parts":[[2021,5,25]]},"published-print":{"date-parts":[[2021,6,30]]}},"alternative-id":["10.1183\/16000617.0026-2021"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0026-2021","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}